Levofloxacin versus TMP/SMX		Adjusted Odds Ratio		
Groups	No.	(95% CI)	P value	
Primary Cohort (Bloodstream and Respiratory Infection)	1580	0.82 (0.62-1.09)	0.17	
Respiratory Infection	1452	0.79 (0.58-1.06)	0.12	
No Mechanical Ventilation	1456	0.80 (0.58-1.09)	0.16	-
Therapy Initiated Empirically	89	0.17 (0.02-1.36)	0.09	_
				0 1 2
				Favors Favors Trimethoprim- Levofloxacin sulfamethoxazole

Appendix Figure 2. Odds Ratios of Mortality for Levofloxacin versus Trimethoprim-sulfamethoxazole Targeted Therapy Among Primary Cohort and Sub-populations of Interest. These results represent post-hoc analyses completed with adjustment for time-to-culture with sub-populations that yielded statistical significance in the primary analysis. Boxes depict hazard ratios with horizontal lines showing the respective 95% confidence intervals.

^{*}Excluding drugs with known activity against S. maltophilia other than Trimethoprim-sulfamethoxazole and Levofloxacin (Appendix Table 4)

[†]Unadjusted data calculated using Fisher's exact test

[‡] Adjusted values were calculated using logistic regression after controlling for baseline patient and hospital level factors. Clinically relevant subpopulations were also analyzed for potential disparate impacts on mortality.